137 results about "Drug Dissolution" patented technology

The invention relates to the technical field of preparation of biological materials and pharmaceutical preparations, in particular to organic composite hydrogel as well as a preparation method and application thereof. The specific preparation method comprises the following steps: dissolving a targeted drug in orthoester to obtain a targeted drug-orthoester solution; the preparation method comprises the following steps: mixing an oxidized dextran solution, a targeted drug-orthoester solution and a carboxymethyl chitosan solution, carrying out vortex treatment, and standing to prepare the organic composite hydrogel. The solubility of the targeted drug in the hydrogel is improved by utilizing orthoester, the orthoester can carry the targeted drug to efficiently escape from the hydrogel, and the targeted drug can be self-assembled to form nanoparticles along with degradation of the orthoester in the escape process, so that the retention capacity of the targeted drug at a tumor site is enhanced, and the targeting drug can be used for treating tumor tumors. The drug enrichment capacity is improved, meanwhile, the toxic and side effects of the whole body are reduced, and the problems that nano-drugs are poor in solubility, still prone to being removed after intravenous administration and poor in enrichment effect at tumor sites are solved.

The invention belongs to the technical field of anhydrous emulsions, and discloses an anhydrous self-emulsifying drug-loaded emulsion based on a deep eutectic solvent and a preparation method thereof.The preparation method comprises the following steps that 1, betaine and a hydrogen bond donor are mixed, the deep eutectic solvent is prepared through a mixed heating method, a drug is dissolved in the deep eutectic solvent, and a drug solution is prepared; the hydrogen bond donor is levulinic acid or lactic acid; (2) mixing Tween 80 and Span 80 according to a mass ratio of (1-2): 1 to obtain a surfactant, adding absolute ethyl alcohol as a co-emulsifier, adding isopropyl myristate, and uniformly stirring and mixing to obtain a dispersion liquid; and (3) dropwise adding the drug solution in the step (1) into the dispersion liquid in the step (2), and stirring at the same time to finally form the anhydrous self-emulsifying drug-loaded emulsion. According to the invention, the loading capacity, the stability and the bioavailability of the medicine can be obviously improved; in addition, the efficiency of transdermal drug delivery of the emulsion is high, and the emulsion can be applied to skin external preparations.

The invention discloses a pH response hydrogel microneedle, which comprises a microneedle substrate, microneedle tips are arranged on the microneedle substrate, the height of the microneedle tips is 100-1600 microns, the diameter of the tip ends of the microneedle tips is 5-15 microns, and the density of the microneedle tips is 200-1000 pieces per square centimeter. The preparation method comprises the following steps: preparing a hyaluronic acid solution for the microneedle substrate, preparing a methacrylated chondroitin sulfate solution for the microneedle tip, preparing methacrylated orthoester, preparing orthoester, preparing a non-steroidal anti-inflammatory drug solution, preparing a microneedle tip solution, preparing the microneedle and demolding the microneedle to prepare the complete soluble microneedle patch. The invention has the advantages of high drug efficiency, high efficiency in dissolving fat / water drugs, and long-acting slow release.

The circulating stirring and dispensing device for mineral separation comprises a support and further comprises a body internally provided with a stirring assembly, a stirring barrel and a stirring motor. The stirring assembly comprises a first stirring rod, a second stirring rod and a stirring motor; the first stirring rod and the second stirring rod sleeve the rotating shaft from top to bottom; a rotating shaft at the bottom of the stirring barrel penetrates through the filter screen; the bottom of the body is provided with a pair of lead-out pipes with electromagnetic valves, the body is arranged on the support, mineral separation and medicine preparation can be circularly stirred, and the device has the advantages that different solid agents and liquid agents can be evenly mixed and stirred, the agents are rapidly dissolved, and a conveying pipeline cannot be blocked.

The invention relates to the technical field of biodegradable materials, in particular to a polylactic acid microsphere with controllable degradation performance and a preparation method and application thereof. Comprising the following steps: S1, dissolving polylactic acid with the molecular weight of 50-200kDa in an organic solvent to obtain an oil phase, and dissolving a medicine in the solvent to obtain a water phase; s2, adding the water phase into the oil phase to form a W / O primary emulsion; s3, adding the W / O primary emulsion into a solution containing a surfactant with the mass volume concentration of 0.5%-2%, and stirring to form a W / O / W system; s4, performing solvent volatilization on the W / O / W system; and S5, collecting the microspheres, and drying. The particle size of the polylactic acid microspheres can be controlled, the high-quality polylactic acid microspheres with controllable degradation performance and drug release performance are prepared, and different biomedical application requirements are met.

The application belongs to the technical field of drug dissolution and dispersion, and particularly relates to a bunazosin water-based solution preparation and a preparation method. The bunazosin water-based solution preparation provided by the application comprises the following components: bunazosin, gamma-cyclodextrin, lecithin, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, aspartame and water. The above components are mixed to be homogeneous to prepare an oral solution which is uniform, clear and can be stored for a long time. The scheme of the application further enriches the dosage form of bunazosin, improves the convenience of taking bunazosin, and is expected to help improve the oral bioavailability and absorption efficiency of bunazosin. The scheme of the application also provides a reference direction for the mechanism research on the dissolution and dispersion behavior of the insoluble bunazosin macromolecule in a water medium.

A method for improving drug solubility and a drug composite material having improved solubility. The method comprises preparing a silica colloidal suspension from silica nanoparticles having a diameter between 2 nm and 100 nm; rapidly evaporating a solvent by means of controlling the temperature and pressure, so as to obtain a porous surface material with ultra-high density silanol groups retained on the surface; and loading drug molecules. By controlling the size of nanoparticles and the density of silanol groups, drug molecules can be effectively adsorbed under anhydrous conditions, and rapidly desorbed and released in an aqueous environment.

The invention relates to the field of pharmaceutical preparations, and discloses a clopidogrel hydrogen sulfate tablet and a preparation method thereof, and the clopidogrel hydrogen sulfate tablet comprises the following components: 30-50 parts of clopidogrel hydrogen sulfate; 5-15 parts of a double-layer nano permeable membrane material; 3 to 12 parts of a pH sensitive release material; 5 to 12 parts of a supramolecular self-assembled nanoparticle material; 5 to 15 parts of a solubility regulator; 2-5 parts of an ionic crosslinking regulatory factor; 10 to 25 parts of an excipient; 0.5 to 2 parts of a lubricant; 0.5 to 2 parts of a stabilizer; the double-layer nano permeable membrane material comprises the following components in parts by weight: an inner layer material: 5-15 parts of hydroxypropyl # imgabs0 #-cyclodextrin; 3 to 10 parts of polyvinylpyrrolidone; an outer layer material: 2-8 parts of ethyl cellulose; and 2 to 10 parts of hydroxypropyl methylcellulose. The double-layer nano permeable membrane is combined with the pH-sensitive controlled release system, so that the dissolution rate of the medicine is adjustable, and accurate release in different pH environments is realized. The technical effects of improving the dissolution efficiency, optimizing medicine absorption and reducing individual differences are achieved.

The utility model discloses a pretreatment device for medicine inspection. The pretreatment device comprises a medicine dissolving tank, a filtering tank and a medicine dissolving solution collecting tank which are communicated with one another, the medicine dissolving tank is also communicated with a solvent storage tank; a stirring device is arranged in the medicine dissolving tank, the stirring device comprises a stirring shaft rotationally arranged in the medicine dissolving tank and a stirring motor connected with the stirring shaft, a plurality of crushing teeth are arranged on the stirring shaft, and the medicine dissolving tank is sleeved with a grinding cylinder on the outer side of the stirring device; a plurality of filtering holes are formed in the side wall of the grinding cylinder, a plurality of first grinding teeth are further arranged on the side wall of the grinding cylinder, and the first grinding teeth and the smashing teeth are arranged in a staggered mode; and an electric heating sheet is arranged in the solvent storage tank. The device can effectively grind and crush medicines, can also control the dissolving temperature, and greatly improves the crushing and grinding effect and dissolving efficiency of the medicines.

A pyridine amide compound-containing composition and a pharmaceutical composition, a preparation method therefor and a use thereof. The composition comprises an active ingredient and at least one matrix material, wherein the active ingredient is a compound represented by formula I or a pharmaceutically acceptable salt, a stereoisomer, a solvate, an isotopically labeled compound, a polymorph, a metabolite or a prodrug thereof. The composition has a high drug loading capacity, improves drug solubility, and has good stability. The in vivo bioavailability of the composition can reach the same level of bioavailability as that of a clear drug solution.

A glycoside drug oral preparation for treating cerebral ischemic stroke during the recovery period and a preparation method therefor. The glycoside drug is (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-(4-methoxyphenyl)butoxy)tetrahydro-2H-pyran-3,4,5-triol. The oral preparation can provide a high drug loading capacity, release the drug within a short time period, and ensure rapid drug dissolution, and the prepared tablet has high stability, involves a simple preparation process and is suitable for large-scale industrial production.

The present application belongs to the technical field of pharmaceutical preparations, and specifically provides a compound SYN045 soft capsule and a preparation method thereof. The present application adopts a fixed proportion of plant oil and polyoxyethylene glyceryl oleate combination to prepare the content, which helps to reduce the degradation of SYN045 in the content drug solution, ensures the stability of the active ingredient, and obtains a compound SYN045 soft capsule with good drug dissolution, high drug content, low impurity generation, and high bioavailability. Further, through prescription optimization of the soft capsule shell, a fixed proportion of plasticizer is selected, the mass ratio of glycerol and sorbitol is 1:2-3, the transfer of the compound SYN045 to the soft capsule shell is reduced, and thus the quality stability problem of the soft capsule preparation product during drug storage is solved.

The invention provides a drug dissolution degree detection method, system and equipment, a medium and a product. The detection method comprises the following steps: emitting target light into a container from the outside of the container and at a preset position; wherein a solution obtained after medicine is dissolved is stored in the container; acquiring target light intensity information of the solution in the container at each moment within a preset time; and obtaining medicine dissolution information in the container based on the target light intensity information corresponding to different moments. According to the method for detecting the dissolution degree of the medicine, the dissolution degree of the medicine in the container can be detected in time, automatically and accurately, human participation in judgment is not needed, and the use experience of a user is improved.

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

This utility model relates to the field of wastewater treatment technology, specifically to a drug dissolving device for wastewater treatment. The device includes a dissolving cylinder, which comprises a cylinder body. A top cover is fixedly connected to the upper end of the cylinder body, and a bottom plate is fixedly connected to the lower end. The top cover is equipped with a stirring mechanism and a feeding mechanism for quantitatively adding drugs. The bottom plate is equipped with an air blowing mechanism for introducing air into the dissolving cylinder, and a sealing mechanism for sealing the dissolving cylinder is located below the bottom plate. A water pipe for adding water to the dissolving cylinder is installed on the side wall of the cylinder body, and an electrically controlled valve is installed on the water pipe. In this utility model, an air pump is used to pump external air into an annular and radial pipes, and then discharges it into the water through air outlets on the annular and radial pipes, creating surging bubbles in the water. Compared to simply having a stirring mechanism, this device further enhances water flow, thereby significantly increasing the drug dissolving speed.

The present application provides a drug-loaded microsphere for loading polypeptide drugs, the polypeptide drug delivery drug-loaded microsphere is W1 / O / W2 structure, which is composed of polypeptide drug active substance and hydrophilic gel as the inner water phase (W1), organic solvent of water-insoluble polymer as the oil phase (O), and solution containing emulsifier as the outer water phase (W2). The sustained-release microsphere of the present application introduces hydrophilic temperature-sensitive gel and water-insoluble polymer to co-load drugs, increases the hydrophilicity of the carrier, and reduces the solubility of polypeptide drugs by preparing metal ion-polypeptide drug active substance insoluble complex, thereby controlling the drug release behavior. Compared with the conventional microsphere, the sustained-release microsphere of the present application has the advantages of reducing drug burst release, shortening the drug release platform period, making the overall drug release behavior of the drug tend to zero-order release, releasing more stably, and improving the compliance of the microsphere preparation.

The present invention provides a furosemide solid preparation and a preparation method thereof, relating to the technical field of medicine. The solid preparation described in the present invention comprises the following components: furosemide, microenvironment pH regulator, preparation porosity regulator, diluent, disintegrant, lubricant. The microenvironment pH regulator is sodium bicarbonate, and the preparation porosity regulator is hydrophilic AEROSIL 200Pharma. In the present invention, porous AEROSIL 200Pharma is used to adsorb furosemide, and then sodium bicarbonate, the microenvironment pH regulator, is used to adjust the pH value of the saturated solution around the drug particles, which can improve the solubility of the drug and increase the drug dissolution.

The present application relates to a low hepatotoxicity actinomycin D solid dispersion and a preparation method thereof. The low hepatotoxicity actinomycin D solid dispersion product is obtained by co-grinding reaction of actinomycin D, plant source functional natural excipient, flow aid and ball milling beads in a ball milling tank. The solid dispersion is prepared by mechanical chemical grinding, without using organic solvent, avoiding drug degradation in high temperature melting process, easily making the drug and excipient amorphous, improving the drug solubility and bioavailability, having the advantages of high preparation efficiency, low production cost, simple operation, green environmental protection and the like; and the plant source polymer is used as a carrier, the solubilization and synergistic effect are enhanced, the hepatotoxicity of actinomycin D is reduced, which is crucial for safe use of antibiotic drugs, and has positive significance for exploring natural, non-toxic, efficient and multifunctional drug loading system excipient.

The utility model discloses a pharmaceutical experiment dissolver which comprises a bottle body, the top end of the bottle body is fixedly connected with a bottle neck, the top end of the bottle neck is fixedly connected with a feeding port, the top end of the feeding port is provided with a cover box, the top face of the cover box is in a net shape, and the bottom face of the cover box is fixedly connected with a sealing plug. When the medicine dissolving device is used for dissolving medicine, the connecting shaft is inserted into the bottle body, then the motor is driven, in the process, fan blades at the output end of the motor can enable the bottle body to have the upward air draft effect through the vent hole, and therefore the medicine dissolving device can be used for dissolving medicine. The motor drives the connecting shaft to rotate in the cavity of the bottle body, the hinged stirring blades are swung in the cavity of the bottle body, and due to the fact that the shrinking openings are arranged to be an upper group and a lower group, when the stirring blades are swung, stirring and dissolving comprehensiveness can be improved, and stirring and dissolving effects are improved. The dissolving efficiency is further improved.

This utility model discloses a drinking water device for pig farming, relating to the field of pig farming technology. Specifically, it is a drinking water device for pig farming, including a drinker with a water storage device installed on the outside. The drinker has a first slot inside, and a drinker frame is installed in the first slot. A second slot is opened through the outer frame of the drinker, and a displacement device that can move up and down according to the water volume is installed at the bottom of the second slot. A spring plate assembly can drive a switch trigger assembly to move up and down according to the water volume. When moving, it can trigger a motor switch to start or stop the motor from injecting water. This allows water to be automatically injected when the pigs' drinking water is insufficient and automatically shut off when the water volume is sufficient, eliminating the need for manual water injection. The medication is placed in the storage tank of the injection device. While water is being injected, the injection device rotates, allowing for intermittent injection of medication without accumulation, which helps the medication dissolve.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

There is provided a composite having a higher dissolution of a drug, the composite including at least a solid dispersion containing the drug and a carrier other than polyvinylpyrrolidone as well as HPMCAS outside the solid dispersion. More specifically, there is provided a composite including at least a solid dispersion containing at least a drug and a carrier selected from the group consisting of a vinylpyrrolidone-vinyl acetate copolymer, methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate and first hydroxypropyl methyl cellulose acetate succinate; and second hydroxypropyl methyl cellulose acetate succinate outside the solid dispersion.

The present disclosure relates to a method of formulating an injectable drug into a film or sheet. A method of formulating a drug into a film or sheet comprises: dissolving the drug in a premix and optionally in an aqueous medium to form a solution; and casting the solution into a mold in order to form the film or sheet. The medicament is formulated in its dosage form and is characterized by at least one of: a unit dose of less than about 200 mg; a volume of less than about 2 mL; chemical and / or physical stability at less than about 60 DEG C; and a solubility in a solvent medium of more than about 10 mg / mL.

The invention discloses a medicine dissolving device and medicine dispensing equipment, and relates to the technical field of medicine preparation, and the medicine dissolving device comprises a clamping assembly and an oscillation assembly; the clamping assembly comprises a clamping jaw assembly, a first limiting assembly and a second limiting assembly, the clamping jaw assembly is located between the first limiting assembly and the second limiting assembly, and the first limiting assembly and the second limiting assembly can synchronously move in the direction close to or away from the clamping jaw assembly; the oscillation assembly is connected with the clamping assembly through the mounting base plate, and the oscillation assembly is used for driving the clamping assembly to move in a plane. According to the medicine dissolving device, the first limiting assembly and the second limiting assembly synchronously move in the direction close to or away from the clamping jaw assembly so as to limit the two ends of medicine bottles of different sizes and specifications, meanwhile, the vibration assembly can drive the clamping assembly to move in the plane, and the medicine dissolving efficiency can be improved while powder medicine dissolving is achieved. And the risk of shifting of the medicine bottle is reduced.

The utility model discloses a vertical storage tank for preventing medicine precipitation, which relates to the technical field of pharmaceutical equipment and comprises a stirring barrel, a shell is fixedly connected onto the stirring barrel, a feed port is fixedly connected to the top of the shell, two rotating shafts are rotatably connected into the shell, crushing rollers are fixedly connected onto the two rotating shafts, and the crushing rollers are fixedly connected onto the stirring barrel. A gap is reserved between the two crushing rollers, the outer side of the shell is fixedly connected with a second servo motor, the second servo motor is in transmission connection with one rotating shaft, the inner bottom of the shell is fixedly connected with a filter plate, and the upper portion of the filter plate is further movably connected with a rolling assembly. According to the medicine storage tank, medicine is ground and then dissolved, so that the contact area between the medicine and a solvent is increased, the medicine is dissolved more thoroughly, the probability that the medicine is precipitated at the bottom in the medicine storage tank due to the volume or weight is avoided, and the risk of medicine precipitation is reduced.

The present invention relates to an orodispersible tablet comprising carbamazepine or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one binder, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients 5 exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The utility model discloses a medicine dissolving device for imitated medicine analysis, and relates to the technical field of medicine dissolving, in particular to the medicine dissolving device for imitated medicine analysis, which comprises a barrel body and a processing mechanism arranged behind the barrel body and used for fixing the barrel body, the vertical frame is arranged behind the barrel body, the base is fixed at the bottom of the vertical frame, and the shaft brackets are fixed on two sides of the top of the base; the side frame is rotationally installed at the upper end of a shaft frame through a shaft rod, the guide frame is fixed to the rear end of the shaft rod, and the guide groove is formed in the guide frame. The movable frame is arranged on the vertical frame, the driving frames are fixed to the two sides of the bottom of the movable frame, and the rolling wheels are rotationally installed on the rear surfaces of the lower ends of the driving frames and located in the guide grooves; the stirring paddle can be controlled to enter or be separated from the barrel body through lifting of the movable frame, and the execution assembly is controlled to fix or unfix the barrel body.

The utility model provides a coating production wastewater treatment and recycling device, and relates to the field of wastewater treatment. The ejection piece structure is installed at the top end of the device body and provided with a storage structure through a supporting rod, a medicine outlet piece is arranged at the bottom of the storage structure, an opening is formed in the side edge of the bottom of the medicine outlet piece, and the opening of the medicine outlet piece is located in the side edge of the stirring paddle. The control storage structure is installed and used, due to the fact that the medicine outlet piece is of a semi-opening structure, air can be stored in the medicine outlet piece, after the sealing plate ascends, the through hole can be opened, medicine is continuously discharged through the through hole, the stirring paddle pushes liquid to impact the medicine outlet piece, the medicine is impacted and dispersed after being discharged, and the medicine is rapidly dissolved and mixed while being dispersed; the mixing efficiency and the treatment efficiency are improved, and the problems that in the using process of a common coating production wastewater treatment and recycling device, medicine dissolving is strenuous after medicine adding, and the dispersion effect is limited are solved.

The invention discloses a preparation method of inositol nicotinate tablets, and belongs to the technical field of pharmaceutical preparations. By optimizing the existing process and coating components, stable dissolution of drugs is realized, and the method comprises the following steps: dispersing inositol nicotinate in mixed oil to prepare an oil phase, mixing and emulsifying the oil phase and a water phase, performing spray drying to obtain drug milk powder, coating the drug milk powder with modified chitosan, and directly tabletting the coated drug milk powder and auxiliary materials. The preparation method comprises the following steps: uniformly dispersing inositol nicotinate in mixed oil to promote the inositol nicotinate to maintain the uniformity of the drug content in the subsequent process, and adsorbing solid particles on the surfaces of drug-containing oil drops through an emulsification technology to protect the drug components; coating components are reasonably designed, so that fixed-point release of the medicine is realized, the medicine is endowed with anti-pressure ability, and the medicine can be directly tableted; and the coated medicine particles are mixed with auxiliary materials and then are directly tableted, so that the process is simplified, and the coating structure of the medicine particles is protected at the same time. The preparation method can prepare the inositol nicotinate tablet with stable drug dissolution, and the inositol nicotinate tablet is good in taste and small in stimulation to gastric mucosa.

The invention provides a novel metformin hydrochloride enteric-coated preparation, which is an oral dosage form prepared from a therapeutically effective amount of biguanide compound and pharmaceutically acceptable auxiliary materials, and is characterized in that the dissolution rate of metformin hydrochloride in a medium with the pH value of 4.5 within 120 minutes is not higher than 15%; and the dissolution rate of metformin hydrochloride in a medium with the pH value of 6.8 within 20 minutes is not lower than 85%, preferably, the dissolution rate in a medium with the pH value of 4.5 within 120 minutes is not higher than 7.5%, and the dissolution rate in a medium with the pH value of 6.8 within 15 minutes is not lower than 85%. The metformin hydrochloride enteric-coated preparation meeting the technical requirements of medicine dissolution improves the gastrointestinal tract tolerance of metformin hydrochloride and reduces adverse reactions caused by medicines under the condition that the hypoglycemic curative effect is not reduced or even improved, can be taken before meals, and can also be taken after meals or during meals, so that the metformin hydrochloride enteric-coated preparation is suitable for clinical application. The medicine taking compliance of a patient is improved.